Medicamen Biotech Limited (IN:MEDICAMEQ)

:MEDICAMEQ

MEDICAMEQ

Medicamen Biotech Limited

RESEARCH TOOLSreports

Want to see IN:MEDICAMEQ full AI Analyst Report?

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹220.00 - ₹454.00

Previous CloseN/A

Volume10.37K

Average Volume (3M)2.40K

Market Cap

₹3.69B

Enterprise Value₹3.67B

Total Cash (Recent Filing)₹436.79M

Total Debt (Recent Filing)₹386.49M

Price to Earnings (P/E)56.5

Beta1.40

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.26%

Share Statistics

EPS (TTM)6.94

Shares Outstanding13,562,815

10 Day Avg. Volume3,620

30 Day Avg. Volume2,395

Financial Highlights & Ratios

PEG Ratio-2.50

Price to Book (P/B)2.95

Price to Sales (P/S)3.86

P/FCF Ratio-52.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Solid Balance Sheet And Moderate LeverageA reasonable debt-to-equity ratio and a solid equity ratio indicate durable solvency and financial flexibility. Satisfactory ROE shows management can generate returns from equity capital. This structural strength supports investment, borrowing capacity, and resilience across 2-6 months.

Healthy Operating (EBIT/EBITDA) And Gross MarginsRelatively healthy EBIT/EBITDA and gross margins reflect efficient cost structure and pricing power in core products. Durable margin strength helps absorb revenue variability and supports long-term profitability, enabling reinvestment and competitive defense over the medium term.

Established Pharma Business Model With Rx And ExportsA business model centered on Rx finished-dose formulations and export markets provides recurring demand, regulatory entry barriers, and geographic diversification. Manufacturing and marketing capabilities create a durable platform for sustained revenue streams and product lifecycle opportunities.

Bears Say

Negative Operating Cash Flow And Negative Free Cash FlowPersistent negative operating and free cash flow undermines internal funding for capex, working capital, and R&D. Over 2-6 months this reduces financial flexibility, may force external financing or cutbacks, and raises execution risk for growth initiatives.

Inconsistent And Recent Declining Revenue TrendA declining and inconsistent top-line trend limits scale economies and pressures long-term margins. Continued revenue contraction hampers ability to absorb fixed costs, slows product investment, and reduces bargaining power with distributors and regulators over the medium term.

Volatile Net Profit Margins Despite Solid Gross MarginsNet-margin volatility signals sensitivity to SG&A, one-offs, or financing costs despite stable gross margins. This unpredictability weakens earnings visibility, complicates capital allocation and dividend planning, and can impair investor confidence over several quarters.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

3M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹220.00 and its highest was ₹454.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹3.69B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Jun 03, 2026 which is in 13 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Feb 13, 2026. The company reported ₹1.613 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.613.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Notavailable dividend of ₹1 which represents an annual dividend yield of 0.26%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.613 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.671%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, and ointments. It also provides oral rehydration solution, mouth wash, and dental care products. The company was incorporated in 1993 and is based in New Delhi, India.